Last reviewed · How we verify
Yuxuebi tablet
Yuxuebi tablet is a Small molecule drug developed by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.. It is currently FDA-approved.
The Yuxuebi tablet is a small molecule glucocorticoid receptor agonist used to treat Ankylosing Spondylitis. It is being studied in a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate its efficacy and safety in treating night pain associated with Ankylosing Spondylitis.
At a glance
| Generic name | Yuxuebi tablet |
|---|---|
| Sponsor | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS). (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yuxuebi tablet CI brief — competitive landscape report
- Yuxuebi tablet updates RSS · CI watch RSS
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Yuxuebi tablet
What is Yuxuebi tablet?
Who makes Yuxuebi tablet?
What development phase is Yuxuebi tablet in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing